DETAILED ACTION
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
2. This Office Action is responsive to the amendment filed on 01/28/2026.
3. Claims 1, 43, 71-76, 79-81, 87,123-130 are pending. Claims 125 or 126, 130 are under examination on the merits. Claims 125-126 are amended. Claim 130 is newly added. Claims 1, 43, 71-76, 79-81, 87, 123-124, 127-129 are withdrawn to a non-elected invention from further consideration.
4. The objections and rejections not addressed below are deemed withdrawn.
5. Regarding claim 125, since no prior art is found that anticipates or renders obvious the elected species, the search of the Markush-type claim is further extended.
Claim Rejections - 35 USC § 102
6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
7. Claims 125-126 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wallace et al. (Rational Tetraarylporphyrin Syntheses: Tetraarylporphyrins from the MacDonald Route, J. Org. Chem. 1993,58, 7245-7257, hereinafter “Wallace).
Regarding claims 125-126: Wallace discloses a compound of 43 (Page 7251, compound 43) which is identical to the instant compound of HKOBUDAQQYMHFJ (US Pub. No. 2022/0403229 A1, Fig. 14).
PNG
media_image1.png
146
118
media_image1.png
Greyscale
PNG
media_image2.png
160
228
media_image2.png
Greyscale
Claim Rejections - 35 USC § 103
8. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
9. Claim 130 is rejected under 35 U.S.C. 103(a)(1) Wallace et al. (Rational Tetraaryl porphyrin Syntheses: Tetraarylporphyrins from the MacDonald Route, J. Org. Chem. 1993,58, 7245-7257, hereinafter “Wallace) in view of pubchem.ncbi.nlm.nih.gov (PubChem database).
Regarding claim 130: The disclosure of Wallace is adequately set forth in paragraph 7 above and is incorporated herein by reference. Wallace does not expressly teach WDIVEVPYH BKUKW compound corresponding to (4-nitrophenyl)-(5-methyl-oxazol-2-yl)-methanone.
However, based on the chemical name, the compound (4-nitrophenyl)-(5-phenyloxazol-2-yl)methanone is identified with CID 10968386 in the pubchem.ncbi.nlm.nih.gov (PubChem database). The compound is a heterocyclic compound with a molecular formula of C16H10N2O4, combining a 4-nitrophenyl group and a 5-phenyloxazole (not 5-methyloxazole) moiety linked by a carbonyl bridge (.
PNG
media_image3.png
232
240
media_image3.png
Greyscale
PNG
media_image4.png
196
250
media_image4.png
Greyscale
Thus, the subject matter as a whole would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention was made, since closely related homologs, analogs and isomers in chemistry may create a prima facie case of obviousness. In re Dillon 16 USPQ 2d 1897, 1904 (Fed. Cir. 1990); In re Payne 203 USPQ 245 (CCPA 1979); In re Mills 126 USPQ 513 (CCPA 1960); In re Henze 85 USPQ 261 (CCPA 1950); In re Hass 60 USPQ 544 (CCPA 1944).
Response to Arguments
10. Applicant’s arguments with respect to claims 125-126, 130 have been considered but are moot because the arguments do not apply to any of the references being used in the current rejection.
11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
Examiner Information
12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bijan Ahvazi, Ph.D. whose telephone number is (571)270-3449. The examiner can normally be reached on Mon-Fri 9.00 A.M. -7 P.M..
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached on 571-272-1130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/Bijan Ahvazi/
Primary Examiner, Art Unit 1763
02/17/2026
bijan.ahvazi@uspto.gov